EUVIMEDEUVIMED entdecken
Crossref

Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives

Tasneem Al Anta, Ola Al Shehadat, Jalal Taneera, Shereen M Aleidi, Ahmad A Abuhelwa, Karem H Alzoubi, Mohammad H Semreen, Waseem El Huneidi, Eman Abu Gharbieh, Yasser Bustanji

Pharmacy Practice · 12.03.2026 · 24 (1) · 1-13

DOI: 10.18549/pharmpract.2026.1.3337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy Practice, online erschienen am 12.03.2026. Verfasst von Tasneem Al Anta und 9 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Anta, T. A., Shehadat, O. A., Taneera, J., Aleidi, S. M., Abuhelwa, A. A., Alzoubi, K. H., Semreen, M. H., Huneidi, W. E., Gharbieh, E. A., & Bustanji, Y. (2026). Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives. Pharmacy Practice, 24(1), 1-13. https://doi.org/10.18549/pharmpract.2026.1.3337

Vancouver

Anta TA, Shehadat OA, Taneera J, Aleidi SM, Abuhelwa AA, Alzoubi KH, et al. Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives. Pharmacy Practice. 2026;24(1):1-13. doi:10.18549/pharmpract.2026.1.3337

BibTeX
@article{Anta2026,
  author = {Anta, Tasneem Al and Shehadat, Ola Al and Taneera, Jalal and Aleidi, Shereen M and Abuhelwa, Ahmad A and Alzoubi, Karem H and Semreen, Mohammad H and Huneidi, Waseem El and Gharbieh, Eman Abu and Bustanji, Yasser},
  title = {Dual inhibition of PI3K and mTOR in cancer therapy: Mechanisms, clinical potential, and future perspectives},
  journal = {Pharmacy Practice},
  year = {2026},
  volume = {24},
  number = {1},
  pages = {1--13},
  doi = {10.18549/pharmpract.2026.1.3337}
}
Kostenlos starten →